Notably, pharmacological inhibition of Cxcr4b signalling by application of two CXCR4 antagonists, namely AMD3100 and IT1t, recapitulated the angiogenesis phenotype of cxcr4b genetic knockouts with significant reduction of abnormal vasculature associated to granulomas. The gene discussed is CXCR4; the disease is Granuloma.